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Accepted 1 August 2014; Published online 2 October 2014AbstractObjectives: To describe the use of systematic reviews or overviews (systematic reviews of systematic reviews) to synthesize quanti-
tative evidence of intervention effects across multiple indications (multiple-indication reviews) and to highlight issues pertaining to such
reviews.
Study Design and Setting: MEDLINE was searched from 2003 to January 2014. We selected multiple-indication reviews of interven-
tions of allopathic medicine that included evidence from randomized controlled trials. We categorized the subject areas evaluated by these
reviews and examined their methodology. Utilities and caveats of multiple-indication reviews are illustrated with examples drawn from
published literature.
Results: We retrieved 52 multiple-indication reviews covering a wide range of interventions. The method has been used to
detect unintended effects, improve precision by pooling results across indications, and examine scientific hypotheses across disease
classes.
Conclusion: Systematic reviews of interventions are typically used to evaluate the effects of treatments, one indication at a time. Here,
we argue that, with due attention to methodological caveats, much can be learned by comparing the effects of a given treatment across many
related indications.  2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http://
creativecommons.org/licenses/by/3.0/).
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Key findings
 There can be benefits and new insights when using
systematic reviews to compare and combine the ef-
fects of a treatment across a range of different
indicationsdmultiple-indication reviews.
What this adds to what was known?
 Multiple-indication reviews are increasingly being
used to evaluate both desirable and unintended
treatment effects, to improve the precision of effect
estimates, and/or to explore potential effect modi-
fication by treatment indication.
What is the implication and what should change
now?
 Producers and commissioners of systematic re-
views and developers of clinical guidelines should
consider using multiple-indication reviews instead
of, or in addition to, reviews focusing on a single
indication.
 Attention needs to be given to heterogeneity, po-
tential confounding factors, and various biases at
both trial and review level when undertaking a
multiple-indication review.
 Suitable statistical methods can be used to examine
and allow for variations both between individual
studies and between different indications.
for synthesizing evidence to inform clinical and policy de-
cisions. In a typical scenario of undertaking evidence syn-
thesis for these purposes (such as a Cochrane systematic
review and a health technology assessment report), a
narrowly focused question or ‘‘decision problem’’ is formu-
lated, which specifies the patient population, interven-
tion(s), comparator(s), and outcome(s) to be covered. This
approach allows evidence synthesis to be conducted within
a clearly defined scope, which ensures that the task is
manageable under a tight timeline and that the reviewed
evidence is directly applicable to the question being set.
Nevertheless, it is not uncommon that such an exercise
produces inconclusive findings because of insufficient evi-
dence. It also ignores theoretical and practical learning that
can be achieved by taking a broader approach, such as com-
parisons of different treatments for a given indication [2],
and ‘‘meta-epidemiologic studies’’ that compare the effect
of study design on findings [3].
This article is concerned with a type of review that goes
beyond the common approach of looking at a specific pa-
tient population (indication) and instead examines the ef-
fects of a given treatment across different indications. We
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of a given intervention are evaluated over multiple clinical
indications or diseases, as ‘‘multiple-indication reviews.’’
In this article, we describe the use of such reviews in recent
literature and highlight the potential contributions and
methodological considerations of their use with some
examples. We focus our attention on synthesis of RCT
evidence on the effectiveness and harms of allopathic med-
icine and suggest other possible uses of the method in the
discussion.
2. Systematic review
2.1. Method of review
2.1.1. Search strategy
There is no standardized terminology for reviews of
studies across multiple indications. As we shall see, a num-
ber of different terms are used to describe this type of re-
view, and authors may conduct a multiple-indication
review without giving it any particular moniker. After
several iterations, we devised a search strategy that aims
to capture systematic reviews and meta-analyses that have
examined evidence for a treatment across different indica-
tions. As some of the multiple-indication reviews known
to us were undertaken in the form of a review of systematic
reviews (often termed ‘‘overviews’’), the search strategy
also specifically targets this type of study. The final search
strategy is shown in Appendix A at www.jclinepi.com. We
searched the MEDLINE database for articles published in
the English language between January 2003 and January
2014. In addition, Cochrane overviews were sought by
searching The Cochrane Database of Systematic Reviews
using the text word ‘‘overview.’’ The main purpose of this
search was to capture a sufficiently wide range of multiple-
indication reviews to describe the rationale and methods
used.
2.1.2. Study selection
Titles and abstracts of the records retrieved from the
search were sifted by at least two of the authors indepen-
dently. Full-text articles were obtained for records that were
considered potentially relevant by at least one of the re-
viewers. Final decisions on inclusion and exclusion were
made by consensus between two of the authors according
to the criteria detailed in the following paragraphs. Discrep-
ancies between authors were resolved through discussion.
A flow diagram for the search and study selection process
is shown in Fig. 1.
Inclusion criteriadstudies needed to meet all the
following criteria to be included:
1. A systematic review of RCTs, an overview of system-
atic reviews of RCTs, or an analysis of individual pa-
tient data from RCTs in a drug development program.
A systematic review is defined as having reported an
explicit literature search strategy.
Fig. 1. Flow diagram of literature search and study selection process.
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RCT.
3. Examined the effect (either intended or unintended)
of an intervention for a given outcome in at least
two named indications.
4. Published from 2003 onward.
Additionally, methodological articles that discussed the
use of, and issues related to, multiple-indication re-
views were also retained. These articles are described in
Section 4.
Exclusion criteriadsystematic reviews or overviews
that met any of the following criteria were excluded:
1. Examined a broad group of heterogeneous interven-
tions (such as Web-based interventions or
telemedicine).
2. Focused on complementary and alternative medi-
cines, most of which have been tried in a wide variety
of (not necessarily related) disease conditions.3. Focused on service delivery interventions that are not
targeted at individual patients.
4. Looked at the effects of an intervention in two popu-
lations defined by the presence or absence of a dis-
ease condition (eg, management of obesity with or
without diabetes).
5. Editorials, letters, and commentaries that do not pre-
sent an original systematic review or overview.
Systematic reviews that were superseded by a more
recent version and multiple-indication systematic reviews
that had been covered in more recent multiple-indication
overviews were also excluded.2.1.3. Data extraction and synthesis
Included studies were examined, and data were extracted
for the following attributes by one author using a structured
coding framework (Table 1):
Table 1. Characteristics of included multiple-indication reviews (n 5 52)
Characteristics n (%)
Form of review
Systematic review of individual randomized controlled trials (RCTs) 34 (65)a
Overviews (systematic review of systematic reviews) 15 (29)
Both (overviews that assessed both systematic reviews and individual RCTs) 3 (6)
Year of publication
2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014b
0 1 2 4 5 3 6 6 10 6 7 2
Type of intervention
Pharmacotherapy (including immunotherapy) 32 (62)
Interventional procedure (including surgery and procedure involving medical devices) 9 (17)
Nutritional therapy 4 (8)
Physical therapy 4 (8)
Cognitive, behavior, and psychological therapy 3 (6)
Condition/indication included in the review
Painful conditions 8 (15)
Surgery 7 (13)
Mental and neurodevelopmental disorders 6 (12)
Cardiovascular diseases 2 (4)
Cancer 2 (4)
Other specific group of conditions 3 (6)
Multiple groups of indications 24 (46)
Focus
Effectiveness 19 (37)
Harm 13 (25)
Both 20 (38)
Inclusion of observational studies in addition to RCTs
Yes 15 (29)
No 37 (71)
Risk of bias assessment undertaken
Yes 36 (69)
No 16 (31)
Using results of risk of bias assessment
Not applicable (risk of bias not assessed) 16 (31)
Results displayed or discussed but not directly used in quantitative analysis 21 (40)
Results used to exclude lower quality studies 4 (8)
Results used to perform subgroup/sensitivity analysis/meta-regression based on study quality/risk of bias 11 (21)
Presentation of results
Description in text or tabulation
Description of direction of effect/conclusion 6 (12)
Quantitative resultsddata from each arms, P values 2 (4)
Comparative effectiveness (point estimates and CIs) 10 (19)
Graphic (eg, forest plots) 34 (65)
Quantitative analysis (with respect to different indications)
Pooled across different indications without considering between-indication variation 21 (40)
Pooled across indications for some outcomes (eg, adverse events) but not for the others (eg, effectiveness outcomes) 4 (8)
Quantitatively examined variation/heterogeneity between indications with or without pooling across indications 11 (21)
No pooling across different indications and no assessment of variation/heterogeneity between indications (quantitative results
reported/displayed separately for each study/indication)
16 (31)
Abbreviation: CI, confidence interval.
a Three of the reviews involved analysis of individual patient data.
b Searched up to January 2014.
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view (eg, systematic reviews of RCTs, individual
RCT reports, or individual patient-level data).
 The intervention(s), indications, and main outcome(s)
covered by the study.
 Whether there was an assessment of quality or risk of
bias in the studies included in the multiple-indication
reviews (eg, assessment of RCTs using the Cochrane
risk of bias tool [4] in systematic reviews, orassessment of systematic reviews using AMSTAR
[5] in reviews of systematic reviews) and whether/
how the results of the assessment were used to guide
quantitative synthesis.
 How quantitative results were presented (in text, ta-
bles, or graphs such as forest plots).
 Whether an attempt was made to pool results across in-
dications and whether potential variation in treatment
effects between different indications was assessed.
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accuracy, with discrepancies and disagreements resolved
through discussion. We present the results in a table and
select three cases to illustrate the potential use and caveats
of multiple-indication reviews.2.2. Findings of systematic review
Our search retrieved 1,180 unique records, of which 173
were considered potentially relevant. Fifty-two systematic
reviews and overviews met the inclusion criteria after ex-
amination of the full text. Additionally, three relevant meth-
odological articles were located [2,6,7]. A flow diagram of
the study selection process is shown in Fig. 1, and a list of
included and excluded studies can be found in Appendices
B and C at www.jclinepi.com, respectively.
Key features of the included multiple-indication reviews
are summarized in Table 1. Use of the method has increased
over the study decade. Two-thirds (65%) are systematic
reviews of primary studies (three of which analyzed individ-
ual patient data) [8e10], whereas most of the remainder are
overviews of systematic reviews. The reviews cover a wide
range of interventions, such as pharmacologic interventions,
interventional procedures (including surgeries and proce-
dures involving medical devices), nutritional therapy, phys-
ical therapy, and cognitive, behavior, and psychological
therapy. Painful conditions, mental and neurodevelopmental
disorders, conditions requiring surgery, and cardiovascular
diseases are common groups of indications within which
multiple-indication reviews are conducted. Pain, mortality,
infection, and various other adverse events are among the
most frequently examined outcomes.
Most of the included reviews focused specifically on
effectiveness (37%) rather than on unintended effects
(25%), whereas the remainder examined both types of
end points (38%). Two-thirds of the reviews (69%) assessed
the risk of bias or quality of studies they included, and of
these, 40% used the results to inform their approach to
the analysis. The majority of studies (65%) presented quan-
titative results in graphic format (eg, forest plots).
The multiple-indication reviews that we identified have
adopted three broad approaches in terms of presentation
and analysis of quantitative data:
1. Presenting results separately for each indication in a
narrative approach.
2. Pooling of results across indications.
3. Examining the variation in effect sizes between
different indications with or without pooling across
indications.
The chosen approach appears to reflect the purpose of a
given multiple-indication review. We shall expand on this
issue in the case studies and discussion sections. Statistical
pooling across indications was not attempted in 18 (35%)
of the studies. An explicit reason for not pooling was given
in only 4 of these 18 cases (perceived clinical heterogeneityin three, while pooling was deferred for a separate article in
the remaining case).
There are as yet no indexed terms in electronic databases
for multiple-indication reviews. Different names such as
‘‘agenda-wide review’’ [11], ‘‘umbrella review’’ [2], and
‘‘panoramic meta-analysis’’ [6,12] have been used in the
literature to describe multiple-indication reviews. We use
‘‘multiple-indication review’’ as it is the least ambiguous
term and recommend its use in future studies for this reason.
A result of lack of agreed terminology implies that our
search strategy, despite several iterations of piloting, could
not have uncovered all multiple-indication reviews. For
example, many systematic reviews of adverse drug effects
may have included data from trials conducted in different
disease conditions without explicitly mentioning the
multiple-indication nature of the review. Our intention
is to identify a sufficient number of examples covering
different clinical areas to inform a critical examination and
discussion of the topic. Our search of recent literature sug-
gests this approach to evidence synthesis is on the rise,
and hence, a critique of the method is timely.3. Case studies
There are three broad nonexclusive uses of multiple-
indication reviews (of RCTs or systematic reviews of
RCTs)dto detect unintended effects, improve estimates of
effectiveness, and examine heterogeneity of effect across dis-
ease groups. We have selected three case studies to demon-
strate each of these uses of multiple-indication reviews.
3.1. Detecting unintended effects
It is often sensibly argued that although the effectiveness
of a treatment is appropriately evaluated by RCTs, detection
of unintended effects must usually rely on othermethods [13].
First, the unintended effects will be expected to be the same
regardless of the indication for the intervention [14]. Second,
RCTs typically have low statistical power for the detection of
unintended effects [14]. The Cochrane handbook states that
‘‘many adverse events are too uncommon or too long term
to be observed within randomized trials’’ [15]. For these rea-
sons, a typical systematic review of controlled trials focusing
on a specific indication may not provide sufficient evidence
on the adverse effects profile of an intervention. However,
combining evidence from multiple indications will improve
ability to detect unintended effects. Broadly, two types of
unintended effects can be considered [16]:
 Rare unexpected effects, such as agranulocytosis in
association with carbamazepine.
 Small, but important, increases in common symptoms
or diseases, such as cardiovascular disease in associ-
ation with COX-2 inhibitors.
The signal-to-noise ratio is higher with the former than
the latter scenario. As a consequence, reporting systems
Fig. 2. Forest plot of meta-analyses concerning effectiveness of adjuvant chemotherapy after surgery vs. surgery alone in different cancer types.
With kind permission from Springer Science þ Business Media (Fig. 2 of Bowater et al.) [17].
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mon disease is much more problematic; these untoward ef-
fects cannot be detected by denominator-free reporting
systems, yet they are likely to be missed by trials in single
diseases [16]. It is in this second situation that comparisons
across indications are particularly useful; by providing a
substantial boost to sample size, they increase the probabil-
ity of identifying a ‘‘signal in the noise.’’ The caveat here is
that the necessary information must have been collected
and reported for the trials that make up the studies included
in the synthesis.
Our example here is a multiple-indication review exam-
ining the risk of cancer after treatment with tumor necrosis
factor alpha inhibitors [8]. The authors boosted data from
74 RCTs in rheumatoid arthritis with 43 trials across a
range of other conditions (providing a null result withinnarrower confidence limits than would otherwise have been
the case).3.2. Improving estimates of effectiveness
Perhaps, a more controversial use of multiple-indication
reviews is to improve estimates of effectiveness. Hemming
et al. [6] suggested the idea of ‘‘borrowing strength’’ by
comparing the estimates of a treatment’s effect size across
a range of similar indications to better evaluate its effective-
ness in an index indication, whereas Ioannidis and Karassa
[11] argue that such an approach can reduce the risk of
false-positive and false-negative study results; a null result
in the index indication is less convincing if across many
other similar indications, the treatment yields strongly pos-
itive results against the same comparator.
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that assessed the effectiveness of adjuvant chemotherapy
after surgery vs. surgery alone, over many different cancer
types [17]. It transpired that the evidence favored chemo-
therapy in most cancers; however, the confidence intervals
included equivalence for some cancers. Fig. 2 immediately
shows the nonsignificant results to be associated with wide
confidence limits suggesting considerable uncertainty. This
result appears more comparable with a common effect
across all cancers than separate effects partitioned across
individual cancers. By concentrating on each condition
individually, guideline writers and opinion leaders may be
too hasty in reaching a conclusion that the treatment should
not be recommendeddborrowing strength by extrapolating
across cancer types may reduce the risk of false-negative
study results, especially where the result is imprecise, and
there are no compelling biological reasons for disease-
specific effects. Conversely, cautions can be raised on
adopting an apparently promising intervention with postu-
lated benefits in many disease areas when examination of
evidence does not suggest a consistent effectiveness across
different indications [18].
3.3. Examining heterogeneity of effect across disease
groups
Multiple-indication reviews can also be used to look for
variations in treatment effects by classes of disease and in this
way examine a scientific hypothesis. In the aforementioned
example, no difference can be discerned in treatment effect
(relative risk reduction) by histologic typedadenocarcinoma
or squamous cell cancer or chemosensitivity of the tumor.
Likewise, a recent overview of prophylactic perioperative
antibiotics in both ‘‘clean’’ and ‘‘dirty’’ operations (Fig. 3)
found no evidence of a difference in the odds ratio of postop-
erative infection according to the degree of contamination
[19].4. Discussion and critique
4.1. Deciding what indications to include
By definition, a multiple-indication review differs from a
‘‘typical’’ systematic review of a given intervention in that
more than one indication is included. This raises a question
as to which disease to include in the set. When looking for
unexpected effects, it makes sense to include all the condi-
tions for which the treatment has been used. This is
because, with a few exceptions such as the interaction be-
tween infectious mononucleosis and ampicillin, adverse
effects are not disease specific [14].
When examining the effectiveness of an intervention,
diseases should be included on the ground that they are or
may be linked by a theoretical constructdas in the exam-
ples of chemotherapy and antibiotics mentioned previously.
Here, the purpose may be to ‘‘borrow-strength’’da methodthat is commonly used in critical care research in which
many conditions such as sepsis, pancreatitis, and massive
trauma are believed to create organ damage through com-
mon pathologic pathways [20]. Conditions can also be
included to test the hypothesis that effects differ according
to theoretical construct, for example, clean vs. contaminated
surgery in the aforementioned example. Likewise, the ef-
fects of antidepressants and cognitive behavior therapy have
been compared across a range of conditions expressly to
explore the theory that their effects are linked through a
common pathway [21,22].4.2. Sources of evidence
Multiple-indication reviews can be undertaken as sys-
tematic reviews of primary studies, in which intervention
effects are pooled across indications and potential differ-
ences in effects are explored across subgroups of trials
defined by indications. Alternatively, the growing number
of published systematic reviews and meta-analyses offers
an opportunity to conduct multiple-indication reviews
through overviews of systematic reviews [23,24]. This
approach provides a practical solution for dealing with
large volume of evidence that would otherwise not be
feasible to review within usual time and resource con-
straints. The development of methodology and potential is-
sues associated with overviews of systematic reviews have
received increasing attention, and comprehensive coverage
of this topic is available elsewhere [25e29]. Multiple-
indication reviews built up from systematic reviews
encounter the problem of ‘‘overlapping’’ where the reviews
include some, but not all, of the same studies. They share
this problem with all studies where topic-specific system-
atic reviews are combined in an overview [12,25]. A strat-
egy must be developed to deal with this issue when it arises,
for instance, by taking into account quality, contemporane-
ousness, and comprehensiveness of individual reviews.
The problem of overlapping does not arise when the
source data comprise individual studies, and this represents
a clear advantage for such an approach where resources
allow.
A multiple-indication review drawing data from existing
systematic reviews will also need to deal with the extra
level of complexity related to potential heterogeneity in
the contributing systematic reviews (in addition to hetero-
geneity in the primary trial evidence) when comparison
and pooling of data between indications is made (see next
section). Reviews of reviews based on a program of system-
atic reviews undertaken using a similar, standardized
approach (such as those of the Cochrane Collaboration)
should mitigate these potential issues [29].4.3. Recognizing and mitigating potential bias
The point of multiple-indication reviews is to examine
for differences across diseases and, if this is present, to
Fig. 3. Forest plot of meta-analyses concerning effectiveness of antibiotic prophylaxis in different surgeries. Pooling over the surgery types, allowing
for both between-study and between-surgery variation, results in a pooled odds ratio of 0.37 (95% credible interval: 0.29, 0.47), which is fairly
convincing evidence that over all surgery types, prophylaxis is effective [6]. Similar results are obtained if the included studies are ordered by base-
line infection risk (ie, control group infection risk) rather than classification system [6]. Adapted with kind permission from John Wiley & Sons Ltd
(Fig. 1 in Hemming et al.) [6].
1316 Y.-F. Chen et al. / Journal of Clinical Epidemiology 67 (2014) 1309e1319explore the cause of these differences, as was done in the
cancer example. This type of heterogeneity is epistemic
to a multiple-indication review and is to be distinguished
from other sources of heterogeneity, which are a cause of
bias in that they may obscure true heterogeneity acrossdiseases or create the appearance of such heterogeneity
when none exists. Such bias may arise when trials of the
same intervention adopt different treatment methods (such
as dose and duration), use different control groups, and/or
are conducted over different time epochs with varied
1317Y.-F. Chen et al. / Journal of Clinical Epidemiology 67 (2014) 1309e1319methodological rigor, across disease types. If the trials in
one disease type were generally small and those in another
were large, then this may lead to publication bias across in-
dications. In addition, where a multiple-indication review is
built up from data from existing systematic reviews of indi-
vidual indications, the methodological quality of the
contributing reviews, their completeness in evidence
coverage, and how up-to-date they are may also add to het-
erogeneity. It is therefore important to examine and, where
relevant, control for these potential confounders across in-
dications when undertaking multiple-indication reviews.
The impact of important potential confounders, such as
methodological quality, can be investigated in the same
way as in a conventional systematic review and raises the
same issuesdsuch as ecological bias. Techniques include
subgroup analysis by the AMSTAR score to take account
of the quality of individual systematic reviews [12] or a
meta-regression approach to generate effect estimates with
review-level covariates being adjusted for [6]. Multiple-
indication reviews based on individual patient data allow
more detailed examination of potential effect modification
by these confounders and more comprehensive statistical
adjustment than those built up from aggregated data [30].
From our perspective, the concerns about bias constitute
grounds for caution in taking a wide-angled view, rather
than an argument to eschew the multiple indication
perspective in favor of considering each treatment effect
in total isolation. We maintain that there is a middle ground
between unquestioning extrapolation of results across dis-
eases and a totally solipsistic focus on each disease, one
at a time.4.4. Analytical approach
There are also methodological issues to consider in the
presentation and synthesis of results. Approximately a third
of the multiple-indication reviews that we found presented
evidence individually for each indication without an over-
arching quantitative analysis. This might present a missed
chance for improving the precision of effect estimates and
reducing type 2 error [31]. Failure to synthesize results
formally may be liable to the problems of ‘‘vote counting,’’
namely not sufficiently taking into account the weight of
evidence and size of effect for individual indications [32].
Displaying results using a forest plot, in which each stem
represents a meta-analysis for a different indication, gives
a clear display of effect estimate, statistical uncertainty,
and variation over indications. The analysis can be taken
further by statistical pooling over indications. There are
arguments for and against such a statistical approach. The
argument against is that this may lend spurious accuracy,
given the possibility that clinical factors and methodological
quality may vary by indication, as discussed in the previous
paragraph. The argument in favor of statistical pooling is
that such heterogeneity can be explored, as in a conventional
meta-analysis, before pooling. Pooling effect estimatesover indication should allow for both between-study and
between-indication variability. In terms of the actual practi-
calities of implementation, the approaches have been
illustrated in Hemming et al. [6]. A formal quantitative data
synthesis can be undertaken using either a two-step fre-
quentist approach or a full Bayesian approach. Both
methods provide a single pooled estimate of the effect
measure over all indications, along with estimates of degree
of heterogeneity between indications. In the two-step
approach, the data are first pooled (first step) within indica-
tions allowing for between-study heterogeneity and then
pooled (second step) across indications allowing for
between-indication heterogeneity. In the Bayesian approach,
the data are modeled as a series of hierarchies similar to a
generalized linear mixed model. These methods therefore
allow for both between-study variability (if random-effects
meta-analysis was used in the pooling of studies within indi-
cation) and between-indication variability (using random
effects).
It is fully accepted that the average effect across many
indications may hide important individual differences
[33]. However, the possibility of hidden subgroup effects
applies to any data set. Indeed, the current interest in strat-
ified medicine represents a search for such subgroups using
molecular mechanisms. At first thought, the ‘‘lumping’’
approach inherent in a review across indications seems to
fly in the face of the ideal of stratified medicine. However,
the two ideas may not be in opposition. Unremitting strat-
ification is liable to yield diminishing returns as the number
of subgroups increases. However, the risk of spurious pos-
itive and false null results can be reduced if the number of
subgroups can be reduced in one dimension (say the organ
of tumor origin), whereas increasing them in another
dimension (say the molecular signature of the tumor). We
argue that a review across indications is an investigative
tool that has its place in science where theory is developed
by synthesizing the results of particular studies to develop,
modify, or refute theory [34].
Although this article has focused on RCTs and system-
atic reviews of RCTs of medical interventions, the idea
could be applied more widely. For instance, studies of
interventions could include observational designs where
statistical techniques to model the effect of potential bias
could be used [35].5. Conclusion
The argument that multiple-indication reviews have an
important role in the detection of adverse effects has at-
tracted little peer criticism, and we believe the methods
can be advocated without further ado. Hammad et al. [36]
have developed a set of criteria, not yet included in the
PRISMA statement, for the detection of unintended conse-
quences of treatment in single-indication meta-analyses but
do not mention multiple-indication reviews. However, we
have encountered resistance to use of this method in the
1318 Y.-F. Chen et al. / Journal of Clinical Epidemiology 67 (2014) 1309e1319assessment of effectiveness. The idea is counterintuitive to
those who have been conditioned to ‘‘compare like with
like’’; the type of systematic review we are proposing sets
out, quite deliberately, to compare (and possibly combine)
things that are clearly not identical. The key, however, is to
appreciate that things may be different in one respect (eg,
the organ in which cancer has arisen, the specialty
involved), while being similar in another (eg, sensitivity
to chemotherapy). Whether they are indeed similar is, of
course, precisely what the synthesis is designed to examine.
In RCTs and ‘‘standard’’ systematic reviews, subgroup
analysis based on patient characteristics (specified a priori
on the basis of biological plausibility) is a widely accepted
tool for exploring potential heterogeneity. The principle of
multiple-indication reviews is no differentdhere, the indi-
vidual indication plays the role of the patient characteristic
(potential effect modifier) of interest. Detecting subgroup
effects is one of the purposes of a ‘‘standard’’ systematic re-
view, just as disease-specific effects can be examined in a
multiple-indication review. We have illustrated the potential
benefits of this wide-angled approach and highlighted is-
sues that require caution when using this method. We main-
tain that there is a middle ground between examining each
disease in isolation and unquestioning extrapolation across
different diseases and that wider adoption of multiple-
indication reviews in evidence synthesis is warranted.Acknowledgment
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